- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed's Omniscan approved in Japan
Hafslund Nycomed's Omniscan MRI contrast agent has been certifiedfor marketing in Japan, the Oslo, Norway, company reported thismonth. Nycomed said that Omniscan will be launched by DaiichiPharmaceutical, Nycomed's Japanese licensee, as soon as
Hafslund Nycomed's Omniscan MRI contrast agent has been certified
for marketing in Japan, the Oslo, Norway, company reported this
month. Nycomed said that Omniscan will be launched by Daiichi
Pharmaceutical, Nycomed's Japanese licensee, as soon as final
price approval is granted by Japanese authorities. Nycomed added
that it has submitted an application for marketing approval in
Japan for Visipaque, its third-generation x-ray contrast agent.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
